What should I know about Sanofi?
Sanofi is a French pharmaceutical company headquartered in Paris that makes prescription medicines and vaccines. It was founded in 1973 as a subsidiary of oil company Elf Aquitaine, merged with Synthélabo in 1999 and bought Aventis in 2004, and took its current name in 2011. It focuses on immunology, rare diseases, neurology, oncology and vaccines. In the second quarter of 2026 it reported net sales of €11.6 billion, up 17.8% at constant exchange rates. Belén Garijo is its chief executive.
What are Sanofi's main drugs?
Dupixent, developed with Regeneron, is Sanofi's biggest product. It treats eczema, asthma and other inflammatory conditions, and in the second quarter of 2026 it passed €5 billion in a single quarter for the first time, at €5.2 billion, up 37.6%. Sanofi's recently launched medicines, including Ayvakit, Altuviiio and Sarclisa, earned €1.3 billion in the quarter. Vaccines made €1.1 billion, down 4.7% because of weaker flu vaccine sales. Sanofi aims for Dupixent to reach about €25 billion a year by 2030, with roughly €10 billion from its newer launches.
What is Sanofi currently developing?
Sanofi said it won seven regulatory approvals in the second quarter of 2026 across immunology, rare disease, oncology and neurology. It also reported positive Phase 3 results for Nexviazyme in infantile-onset Pompe disease and for amlitelimab maintenance treatment in atopic dermatitis (eczema). However, it also stopped the global regulatory submission for amlitelimab and halted development of itepekimab and balinatunfib. The company raised its 2026 forecast and now expects sales growth of around 10% at constant exchange rates, with earnings per share growing slightly faster.
Have there been any controversies involving Sanofi?
Sanofi has faced litigation over two products. In April 2024 it agreed to pay more than $100 million to settle about 4,000 lawsuits alleging that its heartburn medicine Zantac caused cancer. In May 2024 a Hawaii court ordered Sanofi's US subsidiaries and Bristol Myers Squibb to pay a combined $916 million over their marketing of the blood thinner Plavix. The judge found the firms had failed to disclose that it was less effective for around 30% of patients. Both companies said they would appeal.
Is Sanofi publicly traded, and how big is it?
Yes. Sanofi is listed on Euronext Paris (SAN), where it is part of the CAC 40 index, and its American depositary receipts trade on the Nasdaq (SNY). Its market value was about $94 billion on 6 October 2026, down roughly 10% over the previous month and 20% over the previous year. In the second quarter of 2026 it reported net sales of €11.6 billion.